Effects of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism
Assessment of the Effect of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism
1 other identifier
interventional
17
1 country
1
Brief Summary
The Objectives of this study is to determine the effect(s) of daily non-caloric artificial sweetener (NAS) consumption (sucralose or aspartame) on the composition of the bacteria and also to determine the changes in glucose metabolism.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 21, 2015
CompletedFirst Posted
Study publicly available on registry
October 7, 2015
CompletedStudy Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedMarch 13, 2019
May 1, 2018
1.5 years
July 21, 2015
March 11, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fasting Blood Glucose
Fasting blood glucose level and 2-hour oral glucose tolerance test (OGTT).
0-200 mins
Secondary Outcomes (2)
Insulin, glucagon,GIP & GLP-1
4 times during the 12 weeks period
Fecal Microbiome & short chain fatty acids measurements
4 times during the 12 weeks period
Study Arms (2)
Sucralose-Aspartame
EXPERIMENTALGeneric name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
Aspartame-Sucralose
EXPERIMENTALGeneric name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
Interventions
Eligibility Criteria
You may qualify if:
- BMI between 20-25 kg/m2
- Fasting blood glucose (FBG) \< 5.7 mmol/L
- women with regular menstrual cycle.
You may not qualify if:
- probiotic or antibiotic use within 6 months prior to the start of the study
- metabolic or gastrointestinal disorders (diabetes mellitus types 1 and 2, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, phenylketonuria)
- pregnant or lactating women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Richardson Centre for Functional Foods & Nutraceuticals
Winnipeg, Manitoba, R3T 2E1, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
James K Friel, Ph.D.
University of Manitoba
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 21, 2015
First Posted
October 7, 2015
Study Start
July 1, 2016
Primary Completion
January 1, 2018
Study Completion
January 1, 2018
Last Updated
March 13, 2019
Record last verified: 2018-05